Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GlaxoSmithKline Plc receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan (albiglutide)

Wednesday, 26 Mar 2014 09:07am EDT 

GlaxoSmithKline Plc:European Commission granted marketing authorisation for once-weekly diabetes treatment Eperzan.Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control. 

Company Quote

-0.071 -0.15%
21 Nov 2014